GDC-0973 plus vemurafenib versus vemurafenib alone in patients with unresectable stage IIIC or metastatic melanoma harboring BRAF V600 mutations

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-003008-11

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of vemurafenib in combination with Cobimetinib, compared with vemurafenib and placebo, in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by prolongation of progression-free survival (PFS), as assessed by the study site investigator.


Critère d'inclusion

  • BRAFV600-mutation positive patients with unresectable locally
  • advanced or metastatic melanoma